Evidence is provided that solithromycin is a bactericidal against not only fast growing chlamydial organisms but also those slowed by IFN in vitro. At sub-lethal concentrations, Sol impedes homotypic fusion of Chlamydia-containing vacuoles and reduces secretion of the type III secretion (T3S) effector, IncA. Sol may therefore represent a potential new clinical treatment for Chlamydia infections. Selective perturbation of the T3S system suggests a novel mode of antibacterial action for Sol that warrants further investigation.
https://ift.tt/2JuUgxJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου